Skip to content
value.today

Zelos Therapeutics Inc.

Total raised
$14 M
3 rounds on record
Latest round
$2 M
Mar 2012
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Zelos Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2012$2 MNo. 3$2 to $10 million

Zelos Therapeutics Inc.: Raise no. 3, Mar 2012

Investors in this round

6 investors had bought by the notice of Mar 16, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joan Lau · Executive Officer, Director
  • Donald Hayden · Director
  • Joseph Zakrzewski · Director
  • Lily Lam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joan Lau, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2012. Read the notice at the SEC.

equitySEC
Aug 2011$3 MNo. 2$2 to $10 million

Zelos Therapeutics Inc.: Raise no. 2, Aug 2011

Investors in this round

5 investors had bought by the notice of Aug 17, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian MacDonald · Executive Officer, Director
  • Alex Barkas · Director
  • Cynthia Lavoie · Director
  • Joseph Zakrzewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian MacDonald, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2011. Read the notice at the SEC.

equitySEC
May 2009$9 MNo. 1$2 to $10 million

Zelos Therapeutics Inc.: Raise no. 1, May 2009

Investors in this round

16 investors had bought by the notice of Jun 9, 2009: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $13 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Roemer · Executive Officer
  • Brian MacDonald · Executive Officer, Director
  • David Krause · Executive Officer
  • Alex Barkas · Director
  • Colin Goddard · Director
  • Farah Champsi · Director
  • Jeff Courtney · Director
  • Joseph Zakrzewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan Roemer, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 9, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Zelos Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2012).

    SEC Form D · Mar 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2012

That is all the official record says: Zelos Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Zelos Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Zelos Therapeutics Inc.
NameRoleNamed in
Joan LauExecutive officerMar 2012
Brian MacDonaldExecutive officerAug 2011
Alan RoemerExecutive officerJun 2009
David KrauseExecutive officerJun 2009
Donald HaydenDirectorMar 2012
Joan LauDirectorMar 2012
Joseph ZakrzewskiDirectorMar 2012
Lily LamDirectorMar 2012
Alex BarkasDirectorAug 2011
Brian MacDonaldDirectorAug 2011
Cynthia LavoieDirectorAug 2011
Colin GoddardDirectorJun 2009
Farah ChampsiDirectorJun 2009
Jeff CourtneyDirectorJun 2009